查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2017021

血栓除去裝置市場：依系統類型、器材組件、最終用戶和臨床應用分類－2026-2032年全球市場預測

Thrombectomy Devices Market by System Type, Device Component, End User, Clinical Application - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，血栓除去裝置市場價值將達到 32.6 億美元，到 2026 年將成長至 35 億美元，到 2032 年將達到 55.2 億美元，複合年成長率為 7.81%。

主要市場統計數據
基準年 2025 32.6億美元
預計年份：2026年 35億美元
預測年份 2032 55.2億美元
複合年成長率 (%) 7.81%

在器械工程技術的進步、與影像診斷技術的融合以及臨床證據的積累的推動下，血栓除去裝置已從小眾治療方法轉變為多種急性血管疾病治療路徑中不可或缺的工具。本文概述了目前臨床醫生、醫院系統和專科醫療中心日益依賴快速機械方法和聯合療法來清除腦、靜脈和肺循環系統中的阻塞性血栓的現狀。隨著器械特性的不斷發展，不同手術類型和技術模式之間的界限也日益模糊，從而促進了介入神經放射學醫師、血管外科醫師和介入放射科醫師之間的跨學科合作。

因此，醫療器材的採購和使用決策不再僅基於成本或品牌知名度。相反，臨床結果數據、在混合手術環境中的易用性、供應商提供的培訓支援以及供應的連續性正成為主要決定因素。同時，監管機構正在完善醫療設備的核准和上市後監管流程，更加重視真實世界的臨床效能指標。總而言之，隨著不同醫療保健系統對快速再灌注治療和標準化診療路徑的需求不斷成長，這些趨勢凸顯了相關人員需要在臨床需求和營運韌性之間取得平衡的必要性。

設備設計、影像整合和護理路徑最佳化的創新融合如何重塑臨床部署和醫療保健投資。

血栓除去裝置領域正經歷一場變革，其驅動力包括技術創新、流程標準化以及醫療系統優先事項的趨同——即強調速度和治療效果。小型化和材料科學的進步提高了器械在複雜血管解剖結構中的可追溯性和輸送精度，而新的設計則拓展了抽吸和血栓摘取支架平台的治療應用範圍。同時，影像技術和術中導航系統的成熟使得器械定位更加精準，手術時間得以縮短。這些因素共同促進了更好的臨床療效，並拓寬了器械的適用範圍。

評估新徵收的關稅對血栓除去裝置所有相關人員在供應鏈、籌資策略和總成本方面的多方面影響。

美國將於2025年加徵新關稅，進一步加劇了血栓除去裝置已錯綜複雜的全球供應鏈的複雜性。雖然這些關稅旨在保護國內製造商和戰略產業，但也改變了依賴跨境生產專用零件和原料的公司的成本結構。在關鍵市場擁有垂直整合供應鏈的製造商更有能力吸收或緩解關稅帶來的成本壓力，而依賴受影響地區單一供應商的公司則面臨採購波動性加劇的困境。

一項全面的細分分析揭示了設備分類、手術亞型、技術方法、分銷策略和醫療保健環境如何決定臨床和商業性重點。

精細的市場細分觀點揭示了器械選擇、手術適應症、底層技術、分銷管道和終端用戶環境如何全面影響市場動態和臨床工作流程。依器械類型分類，市場可分為抽吸導管和血栓摘取支架，二者在輸送方式、血栓捕獲能力和預期首過效應方面各有不同。臨床醫生會根據病變形態、血管通路複雜程度以及操作者的技術水平選擇合適的器械。依手術類型分類，血栓切除術的適應症包括深層靜脈栓塞症、缺血性中風和肺動脈栓塞，並進一步細分為不同的臨床亞型。具體而言，深層靜脈栓塞症分為遠端型和髂股型，缺血性中風分為循環前閉塞和循環後血栓症，肺動脈栓塞則依血栓大小分為大面積血栓和亞大面積血栓症。這些手術亞型決定了具體的設備設計重點、輔助技術以及所需的臨床醫生技能。

全球市場在臨床基礎設施、管理體制和採用因素方面的區域差異正在塑造個人化的商業化和培訓方法。

區域趨勢差異顯著，每個區域都有其獨特的臨床實踐模式、法規結構和基礎設施成熟度，所有這些因素都會影響器械部署和支援模式。在美洲，成熟的急性中風網路、醫院對混合介入手術室的大量投資以及集中的高品質醫療中心，正在推動對高性能取栓平台和綜合培訓項目的需求。該地區多個國家的報銷方案和急救醫療服務規程也優先考慮快速分流和轉運路線，這直接影響到三級醫療機構的器械選擇和庫存管理政策。

製造商如何將迭代式設備創新、證據產生和擴展服務模式結合起來，以提高臨床應用率並在競爭中脫穎而出？

血栓除去裝置領域的主要企業正面臨快速創新、臨床期望不斷提高以及供應鏈重組的挑戰。產業領導企業優先投資於能夠提高首次手術成功率、更便捷地進入複雜解剖結構並縮短手術時間的產品系列組合。許多公司致力於迭代改進器械，並開發可與影像平台整合、與輔助器具無縫相容的模組化系統。隨著各公司尋求建構能夠帶來可衡量的臨床優勢的綜合手術生態系統，器械創新者與影像和導航服務提供者之間的策略合作也日益普遍。

為製造商、臨床醫生和醫療保健系統提供實用策略，使產品創新、培訓和供應彈性與永續的臨床和商業性成果保持一致。

產業領導者應優先考慮制定協調一致的策略，將產品開發與已驗證的臨床價值、營運流程和供應鏈韌性相結合。首先，設計工作應著重於提高手術效率和通用性，確保設備在臨床醫師遇到的關鍵手術案例中可靠運作。製造商和臨床領導者應合作開發培訓課程和基於模擬的技能提升項目，以縮短學習曲線，並支持產品在醫院和專科醫療中心的推廣應用。同時，投資產生可靠的真實世界數據 (RWE) 並參與註冊研究，將有助於增強臨床信心，並促進相關成果納入指南。

調查方法概述，詳細介紹了確保可靠見解的三角測量方法，包括專家訪談、監管和臨床文獻審查以及交叉檢驗的數據整合。

本分析整合了基於三角測量法的調查方法，結合了與臨床和採購專家進行的初步定性研究、對監管申報文件和器械標籤的詳細審查，以及對同行評審的臨床文獻和手術註冊資料的審查。初步研究包括對介入醫師、血管專家、醫院物資管理人員和行業高管進行結構化訪談，以了解營運挑戰、推廣障礙以及臨床實踐中器械性能的相關考慮。次要資訊包括監管摘要、已發表的臨床試驗、會議論文集和白皮書，這些資料詳細介紹了手術結果、器械特定指標和臨床指南。

策略整合強調創新、證據生成和營運韌性之間的相互作用，以此作為血栓切除治療相關人員長期成功的決定因素。

總之，在器械創新、與影像診斷技術的日益融合以及醫療機構對及時再灌注的需求等因素的推動下，血栓除去裝置在急性血管疾病治療中發揮著日益重要的作用。相關人員必須適應複雜的營運環境，其中手術流程的差異、監管的細微差別以及供應鏈的波動交織在一起。策略成功取決於產品功能與臨床醫生需求的契合度、循證醫學證據的累積以及透過多元化的採購管道和完善的分銷策略來確保營運的韌性。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：血栓除去裝置市場（按系統類型分類）

  • 超音波輔助溶栓
  • 旋轉血栓切除術
  • 溶栓治療
  • 利奧里蒂克栓塞切除術
  • 抽吸血栓切除手術

第9章：血栓除去裝置市場（依器械組件分類）

  • 導管
  • 訪問交付工具
  • 耗材和手術包
  • 輔助和支援設備

第10章：血栓除去裝置市場：依最終用戶分類

  • 研究和學術機構
  • 門診手術中心
  • 醫院
  • 專科診所

第11章：血栓除去裝置市場（依臨床應用分類）

  • 周邊/靜脈
    • 腎/腸系膜血栓症
    • 肺動脈栓塞（PE）
    • 深層靜脈栓塞症（DVT）
  • 神經血管
    • 腦靜脈血栓症
    • 急性缺血性腦中風
  • 心血管系統
    • 周邊動脈血栓症
    • 冠狀動脈栓塞

第12章：血栓除去裝置市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章：血栓除去裝置市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章血栓除去裝置市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國血栓除去裝置市場

第16章：中國血栓除去裝置市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • Acandis GmbH
  • Anaconda Biomed
  • AngioDynamics, Inc.
  • Becton, Dickinson and Company
  • Boston Scientific Corporation
  • Cardinal Health, Inc.
  • Control Medical Technology, LLC
  • Cook Group Incorporated
  • Endocor GmbH
  • Inquis Medical
  • Johnson & Johnson Services, Inc.
  • Kaneka Corporation
  • Koninklijke Philips NV
  • LeMaitre Vascular, Inc.
  • Medico's Hirata Inc.
  • Medtronic plc
  • Meril Life Sciences Pvt. Ltd.
  • Merit Medical Systems, Inc.
  • NeuroVasc Technologies Inc.
  • Nipro Corporation
  • Penumbra, Inc.
  • Rapid Medical, Inc.
  • Stryker Corporation
  • Surmodics, Inc.
  • Teleflex Incorporated
  • Terumo Corporation
  • Uniphar Medtech
  • VESALIO
  • Wallaby Medical Holding, Inc.
Product Code: MRR-030298DFFFC6

The Thrombectomy Devices Market was valued at USD 3.26 billion in 2025 and is projected to grow to USD 3.50 billion in 2026, with a CAGR of 7.81%, reaching USD 5.52 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 3.26 billion
Estimated Year [2026] USD 3.50 billion
Forecast Year [2032] USD 5.52 billion
CAGR (%) 7.81%

Thrombectomy devices have moved from niche interventions to essential tools across several acute vascular care pathways, driven by advances in device engineering, imaging integration, and accumulated clinical evidence. This introduction frames the contemporary landscape where clinicians, hospital systems, and specialty centers increasingly rely on rapid mechanical and combined approaches to remove occlusive thrombi in cerebral, venous, and pulmonary circulations. As device profiles evolve, the boundary between procedure types and technology modalities has become more fluid, prompting interdisciplinary collaboration among neurointerventionalists, vascular surgeons, and interventional radiologists.

Consequently, procurement and utilization decisions are no longer based solely on device cost or brand familiarity. Instead, clinical outcomes data, ease of use in hybrid operating environments, vendor support for training, and supply continuity are central determinants. In parallel, regulatory agencies have refined pathways for device clearance and post-market surveillance, placing greater emphasis on real-world performance metrics. Taken together, these dynamics underscore the need for stakeholders to reconcile clinical imperatives with operational resilience, as the sector adapts to heightened demand for rapid reperfusion therapies and standardized care pathways across diverse health systems.

How converging innovations in device design, imaging integration, and care pathway optimization are reshaping clinical adoption and institutional investments

The landscape for thrombectomy devices is undergoing transformative shifts driven by convergence of technological innovation, procedural standardization, and health system priorities that emphasize speed and outcomes. Miniaturization and material science advances have improved trackability and deliverability in complex vascular anatomy, while novel designs have expanded the therapeutic envelope for aspiration techniques and stent retriever platforms. Simultaneously, imaging modalities and intra-procedural guidance systems have matured, enabling more precise device placement and shorter procedure times, which together support better clinical outcomes and broaden appropriate use criteria.

Regulatory and reimbursement environments are also evolving, with payers increasingly recognizing the downstream cost benefits of timely mechanical reperfusion for stroke and selected pulmonary embolism cases. This shift incentivizes institutions to invest in targeted training, hybrid suite capabilities, and process optimization to maximize first-pass success. Moreover, the industry has seen accelerated collaboration between device manufacturers and clinical networks to generate robust real-world evidence and to speed adoption through structured training programs. As a result, adoption patterns now reflect a balance between innovation adoption curves and pragmatic considerations such as inventory management, staff competencies, and alignment with acute care pathways.

Assessing the multifaceted consequences of newly implemented tariffs on supply chains, procurement strategies, and total cost considerations across thrombectomy device stakeholders

The imposition of new United States tariffs in 2025 introduced a fresh layer of complexity to an already intricate global supply chain for thrombectomy devices. While tariffs aim to protect domestic manufacturing and strategic industries, they have also altered cost structures for companies that rely on cross-border production of specialized components and raw materials. Manufacturers with vertically integrated supply chains in key markets have been better positioned to absorb or mitigate tariff-related cost pressures, whereas firms dependent on single-source suppliers in affected jurisdictions have faced increased procurement volatility.

In response, many stakeholders accelerated active risk management measures including supplier diversification, onshoring of critical production stages, and renegotiation of long-term contracts to secure favorable terms. Distributors and hospital purchasing teams likewise intensified inventory planning to prevent short-term shortages during transitional tariff implementation periods. Importantly, procurement strategies shifted toward evaluating total cost of ownership rather than unit pricing alone, considering factors such as lead time predictability, warranty and service provision, and training support. Going forward, the cumulative impact of tariffs has elevated strategic supply chain resilience to a core competitive attribute for device manufacturers and for health systems seeking uninterrupted access to critical thrombectomy technologies.

Comprehensive segmentation analysis revealing how device class, procedural subtype, technological approach, distribution strategy, and care setting determine clinical and commercial priorities

A nuanced segmentation lens reveals how device choice, procedural indication, underlying technology, distribution approach, and end-user setting collectively shape market dynamics and clinical workflows. Based on device, the market divides into aspiration catheters and stent retrievers, each with distinct profiles for deliverability, clot engagement, and first-pass effect expectations; clinicians select between these device classes according to lesion morphology, vascular access complexity, and operator familiarity. Based on procedure, thrombectomy applications span deep vein thrombosis, ischemic stroke, and pulmonary embolism, with further clinical granularity where deep vein thrombosis is characterized by distal versus iliofemoral presentations, ischemic stroke is classified into anterior circulation versus posterior circulation occlusions, and pulmonary embolism is assessed as massive or submassive cases; these procedural subtypes drive specific device design priorities, adjunctive technologies, and requisite clinician skill sets.

Based on technology, laser assisted, mechanical, and pharmacomechanical approaches provide differentiated mechanisms for thrombus removal or modification, and the choice between them reflects trade-offs among efficacy, procedural duration, bleeding risk, and adjunctive anticoagulation needs. Based on distribution channel, manufacturers and suppliers balance direct sales relationships against online platforms that facilitate expedited procurement and broader geographic reach, influencing training models and post-sale service expectations. Based on end user, ambulatory surgical centers, hospitals, and specialty clinics each impose different operational constraints and purchasing behaviors, where ambulatory settings prioritize streamlined procedural throughput, hospitals emphasize comprehensive on-call coverage and hybrid suites, and specialty clinics focus on subspecialized expertise and case mix. Together, these segmentation dimensions determine product development roadmaps, clinical education investments, and commercialization strategies that align with the procedural mix and care delivery context.

Regional differentiation in clinical infrastructure, regulatory regimes, and adoption drivers shaping tailored commercialization and training approaches across global markets

Regional dynamics vary significantly, with each geography presenting unique clinical practice patterns, regulatory frameworks, and infrastructure maturity that influence device adoption and support models. In the Americas, well-established acute stroke networks, substantial hospital investment in hybrid interventional suites, and concentrated centers of excellence drive demand for high-performance thrombectomy platforms and integrated training programs. Reimbursement structures and emergency medical services protocols in several countries in the region also prioritize rapid triage and transfer pathways, which has a direct bearing on device selection and stocking philosophies at tertiary centers.

Europe, Middle East & Africa presents a heterogeneous landscape where advanced urban centers exhibit rapid uptake of novel thrombectomy technologies while rural and resource-constrained areas face access challenges. Regulatory harmonization efforts in some European jurisdictions streamline market entry for devices, but divergent procurement rules and national health system priorities necessitate differentiated commercialization strategies. In the Asia-Pacific region, rapid investment in stroke care infrastructure and increased procedural volumes in major markets have stimulated local manufacturing partnerships and regional distribution networks. However, variability in clinical training capacity and uneven availability of hybrid environments require tailored educational outreach and flexible service models to support sustained adoption across diverse hospital systems.

How manufacturers are combining iterative device innovation, evidence generation, and expanded service models to strengthen clinical adoption and competitive differentiation

Key companies in the thrombectomy device arena are navigating a landscape defined by rapid innovation, heightened clinical expectations, and supply chain recalibration. Industry leaders are prioritizing investments in product portfolios that enhance first-pass success, facilitate access in tortuous anatomy, and reduce procedural time. Many firms are pursuing iterative device improvements and modular systems that integrate with imaging platforms and offer seamless compatibility with ancillary tools. Strategic alliances between device innovators and imaging or navigation providers have become more commonplace as companies seek to create comprehensive procedural ecosystems that deliver measurable clinical advantages.

Competitive positioning is also influenced by approaches to clinical evidence generation and post-market surveillance. Companies that invest in robust multicenter registries, investigator-initiated trials, and clinician training programs tend to accelerate credibility among high-volume centers and referral networks. In parallel, smaller, more nimble entrants are focusing on niche innovations or cost-efficient manufacturing approaches to address specific procedural gaps or resource-constrained environments. Across the spectrum, manufacturers are enhancing service offerings including hands-on training, simulation curricula, and remote proctoring, recognizing that after-sales support and clinician confidence are pivotal to sustained device utilization.

Actionable strategies for manufacturers, clinicians, and health systems to align product innovation, training, and supply resilience with sustainable clinical and commercial outcomes

Industry leaders should prioritize a coordinated strategy that aligns product development with demonstrated clinical value, operational workflows, and supply chain resilience. First, design efforts must concentrate on improving procedural efficiency and versatility, ensuring devices perform reliably across the key procedural presentations clinicians encounter. Manufacturers and clinical leaders should co-develop training curricula and simulation-based proficiency programs to shorten the learning curve and support diffusion across hospitals and specialty centers. In parallel, investment in robust real-world evidence generation and registry participation will reinforce clinical trust and inform guideline incorporation.

Operationally, organizations must diversify sourcing and consider selective onshoring or dual-sourcing for critical components to mitigate tariff and geopolitical risks. Distribution strategies should blend direct engagement with high-volume centers and digital procurement channels for broader market reach, while maintaining strong after-sales service capabilities. Health systems and procurement teams should adopt total cost of ownership frameworks to evaluate vendor proposals, factoring in service, training, and inventory predictability. Finally, collaboration between manufacturers, payers, and clinical networks to demonstrate value-based outcomes will support sustainable access and appropriate reimbursement pathways, thereby aligning incentives across the care continuum.

Methodological overview detailing a triangulated approach of expert interviews, regulatory and clinical literature review, and cross-validated data synthesis to ensure robust insights

This analysis synthesizes insights derived from a triangulated research methodology that combines primary qualitative engagements with clinical and procurement experts, detailed review of regulatory filings and device labeling, and examination of peer-reviewed clinical literature and procedure registries. Primary research included structured interviews with interventionalists, vascular specialists, hospital supply managers, and industry executives to capture operational challenges, adoption barriers, and real-world device performance considerations. Secondary sources encompassed regulatory approval summaries, published clinical trials, conference proceedings, and white papers that document procedural outcomes, device-specific metrics, and practice guidelines.

Data integrity was assured through cross-validation across multiple information streams, reconciliation of divergent perspectives, and rigorous source attribution. Analytical techniques included thematic synthesis of interview data, technology readiness assessments, and supply chain risk mapping. Limitations of the methodology are acknowledged, including variable transparency in proprietary commercial agreements and the evolving nature of post-market surveillance data. To mitigate these constraints, the research incorporated sensitivity checks and sought corroboration from independent clinical experts to ensure balanced interpretation of trends and strategic implications.

Strategic synthesis emphasizing the interplay of innovation, evidence generation, and operational resilience as determinants of long-term success for thrombectomy stakeholders

In conclusion, thrombectomy devices occupy an increasingly central role across acute vascular care, propelled by device innovation, enhanced imaging integration, and the institutional imperative to deliver timely reperfusion. Stakeholders must adapt to a complex operating environment where procedural variability, regulatory nuance, and supply chain dynamics intersect. Strategic success will hinge upon aligning product capabilities with clinician needs, strengthening evidence generation, and ensuring operational resilience through diversified sourcing and sophisticated distribution strategies.

Looking ahead, organizations that marry technological excellence with comprehensive training and reliable post-sale support will be best positioned to capture long-term clinical trust and utilization. Equally important is the recognition that collaborative efforts among manufacturers, health systems, and payers to demonstrate meaningful patient outcomes will accelerate appropriate access and integration of thrombectomy therapies across broader care pathways. This synthesis should inform executive decision-making, guiding prioritization of investments that balance near-term operational imperatives with sustained clinical impact.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Thrombectomy Devices Market, by System Type

  • 8.1. Ultrasound-assisted Thrombolysis
  • 8.2. Rotational Embolectomy
  • 8.3. Thrombus Fragmentation
  • 8.4. Rheolytic Embolectomy
  • 8.5. Aspiration Thrombectomy

9. Thrombectomy Devices Market, by Device Component

  • 9.1. Catheters
  • 9.2. Access & Delivery Tools
  • 9.3. Consumables & Procedure Kits
  • 9.4. Ancillary / Support Devices

10. Thrombectomy Devices Market, by End User

  • 10.1. Research & Academic Institutions
  • 10.2. Ambulatory Surgical Centers
  • 10.3. Hospitals
  • 10.4. Specialty Clinics

11. Thrombectomy Devices Market, by Clinical Application

  • 11.1. Peripheral / Venous
    • 11.1.1. Renal / Mesenteric Thrombosis
    • 11.1.2. Pulmonary Embolism (PE)
    • 11.1.3. Deep Vein Thrombosis (DVT)
  • 11.2. Neurovascular
    • 11.2.1. Cerebral Venous Thrombosis
    • 11.2.2. Acute Ischemic Stroke
  • 11.3. Cardiovascular
    • 11.3.1. Peripheral Arterial Thrombosis
    • 11.3.2. Coronary Artery Thrombosis

12. Thrombectomy Devices Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Thrombectomy Devices Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Thrombectomy Devices Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Thrombectomy Devices Market

16. China Thrombectomy Devices Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Abbott Laboratories
  • 17.6. Acandis GmbH
  • 17.7. Anaconda Biomed
  • 17.8. AngioDynamics, Inc.
  • 17.9. Becton, Dickinson and Company
  • 17.10. Boston Scientific Corporation
  • 17.11. Cardinal Health, Inc.
  • 17.12. Control Medical Technology, LLC
  • 17.13. Cook Group Incorporated
  • 17.14. Endocor GmbH
  • 17.15. Inquis Medical
  • 17.16. Johnson & Johnson Services, Inc.
  • 17.17. Kaneka Corporation
  • 17.18. Koninklijke Philips N.V.
  • 17.19. LeMaitre Vascular, Inc.
  • 17.20. Medico's Hirata Inc.
  • 17.21. Medtronic plc
  • 17.22. Meril Life Sciences Pvt. Ltd.
  • 17.23. Merit Medical Systems, Inc.
  • 17.24. NeuroVasc Technologies Inc.
  • 17.25. Nipro Corporation
  • 17.26. Penumbra, Inc.
  • 17.27. Rapid Medical, Inc.
  • 17.28. Stryker Corporation
  • 17.29. Surmodics, Inc.
  • 17.30. Teleflex Incorporated
  • 17.31. Terumo Corporation
  • 17.32. Uniphar Medtech
  • 17.33. VESALIO
  • 17.34. Wallaby Medical Holding, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL THROMBECTOMY DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL THROMBECTOMY DEVICES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL THROMBECTOMY DEVICES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL THROMBECTOMY DEVICES MARKET SIZE, BY SYSTEM TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL THROMBECTOMY DEVICES MARKET SIZE, BY DEVICE COMPONENT, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL THROMBECTOMY DEVICES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL THROMBECTOMY DEVICES MARKET SIZE, BY CLINICAL APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL THROMBECTOMY DEVICES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL THROMBECTOMY DEVICES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL THROMBECTOMY DEVICES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES THROMBECTOMY DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA THROMBECTOMY DEVICES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL THROMBECTOMY DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL THROMBECTOMY DEVICES MARKET SIZE, BY SYSTEM TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL THROMBECTOMY DEVICES MARKET SIZE, BY ULTRASOUND-ASSISTED THROMBOLYSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL THROMBECTOMY DEVICES MARKET SIZE, BY ULTRASOUND-ASSISTED THROMBOLYSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL THROMBECTOMY DEVICES MARKET SIZE, BY ULTRASOUND-ASSISTED THROMBOLYSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL THROMBECTOMY DEVICES MARKET SIZE, BY ROTATIONAL EMBOLECTOMY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL THROMBECTOMY DEVICES MARKET SIZE, BY ROTATIONAL EMBOLECTOMY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL THROMBECTOMY DEVICES MARKET SIZE, BY ROTATIONAL EMBOLECTOMY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL THROMBECTOMY DEVICES MARKET SIZE, BY THROMBUS FRAGMENTATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL THROMBECTOMY DEVICES MARKET SIZE, BY THROMBUS FRAGMENTATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL THROMBECTOMY DEVICES MARKET SIZE, BY THROMBUS FRAGMENTATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL THROMBECTOMY DEVICES MARKET SIZE, BY RHEOLYTIC EMBOLECTOMY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL THROMBECTOMY DEVICES MARKET SIZE, BY RHEOLYTIC EMBOLECTOMY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL THROMBECTOMY DEVICES MARKET SIZE, BY RHEOLYTIC EMBOLECTOMY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL THROMBECTOMY DEVICES MARKET SIZE, BY ASPIRATION THROMBECTOMY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL THROMBECTOMY DEVICES MARKET SIZE, BY ASPIRATION THROMBECTOMY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL THROMBECTOMY DEVICES MARKET SIZE, BY ASPIRATION THROMBECTOMY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL THROMBECTOMY DEVICES MARKET SIZE, BY DEVICE COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL THROMBECTOMY DEVICES MARKET SIZE, BY CATHETERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL THROMBECTOMY DEVICES MARKET SIZE, BY CATHETERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL THROMBECTOMY DEVICES MARKET SIZE, BY CATHETERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL THROMBECTOMY DEVICES MARKET SIZE, BY ACCESS & DELIVERY TOOLS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL THROMBECTOMY DEVICES MARKET SIZE, BY ACCESS & DELIVERY TOOLS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL THROMBECTOMY DEVICES MARKET SIZE, BY ACCESS & DELIVERY TOOLS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL THROMBECTOMY DEVICES MARKET SIZE, BY CONSUMABLES & PROCEDURE KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL THROMBECTOMY DEVICES MARKET SIZE, BY CONSUMABLES & PROCEDURE KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL THROMBECTOMY DEVICES MARKET SIZE, BY CONSUMABLES & PROCEDURE KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL THROMBECTOMY DEVICES MARKET SIZE, BY ANCILLARY / SUPPORT DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL THROMBECTOMY DEVICES MARKET SIZE, BY ANCILLARY / SUPPORT DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL THROMBECTOMY DEVICES MARKET SIZE, BY ANCILLARY / SUPPORT DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL THROMBECTOMY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL THROMBECTOMY DEVICES MARKET SIZE, BY RESEARCH & ACADEMIC INSTITUTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL THROMBECTOMY DEVICES MARKET SIZE, BY RESEARCH & ACADEMIC INSTITUTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL THROMBECTOMY DEVICES MARKET SIZE, BY RESEARCH & ACADEMIC INSTITUTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL THROMBECTOMY DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL THROMBECTOMY DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL THROMBECTOMY DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL THROMBECTOMY DEVICES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL THROMBECTOMY DEVICES MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL THROMBECTOMY DEVICES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL THROMBECTOMY DEVICES MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL THROMBECTOMY DEVICES MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL THROMBECTOMY DEVICES MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL THROMBECTOMY DEVICES MARKET SIZE, BY CLINICAL APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL THROMBECTOMY DEVICES MARKET SIZE, BY PERIPHERAL / VENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL THROMBECTOMY DEVICES MARKET SIZE, BY PERIPHERAL / VENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL THROMBECTOMY DEVICES MARKET SIZE, BY PERIPHERAL / VENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL THROMBECTOMY DEVICES MARKET SIZE, BY PERIPHERAL / VENOUS, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL THROMBECTOMY DEVICES MARKET SIZE, BY RENAL / MESENTERIC THROMBOSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL THROMBECTOMY DEVICES MARKET SIZE, BY RENAL / MESENTERIC THROMBOSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL THROMBECTOMY DEVICES MARKET SIZE, BY RENAL / MESENTERIC THROMBOSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL THROMBECTOMY DEVICES MARKET SIZE, BY PULMONARY EMBOLISM (PE), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL THROMBECTOMY DEVICES MARKET SIZE, BY PULMONARY EMBOLISM (PE), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL THROMBECTOMY DEVICES MARKET SIZE, BY PULMONARY EMBOLISM (PE), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL THROMBECTOMY DEVICES MARKET SIZE, BY DEEP VEIN THROMBOSIS (DVT), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL THROMBECTOMY DEVICES MARKET SIZE, BY DEEP VEIN THROMBOSIS (DVT), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL THROMBECTOMY DEVICES MARKET SIZE, BY DEEP VEIN THROMBOSIS (DVT), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL THROMBECTOMY DEVICES MARKET SIZE, BY NEUROVASCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL THROMBECTOMY DEVICES MARKET SIZE, BY NEUROVASCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL THROMBECTOMY DEVICES MARKET SIZE, BY NEUROVASCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL THROMBECTOMY DEVICES MARKET SIZE, BY NEUROVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL THROMBECTOMY DEVICES MARKET SIZE, BY CEREBRAL VENOUS THROMBOSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL THROMBECTOMY DEVICES MARKET SIZE, BY CEREBRAL VENOUS THROMBOSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL THROMBECTOMY DEVICES MARKET SIZE, BY CEREBRAL VENOUS THROMBOSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL THROMBECTOMY DEVICES MARKET SIZE, BY ACUTE ISCHEMIC STROKE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL THROMBECTOMY DEVICES MARKET SIZE, BY ACUTE ISCHEMIC STROKE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL THROMBECTOMY DEVICES MARKET SIZE, BY ACUTE ISCHEMIC STROKE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL THROMBECTOMY DEVICES MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL THROMBECTOMY DEVICES MARKET SIZE, BY CARDIOVASCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL THROMBECTOMY DEVICES MARKET SIZE, BY CARDIOVASCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL THROMBECTOMY DEVICES MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL THROMBECTOMY DEVICES MARKET SIZE, BY PERIPHERAL ARTERIAL THROMBOSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL THROMBECTOMY DEVICES MARKET SIZE, BY PERIPHERAL ARTERIAL THROMBOSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL THROMBECTOMY DEVICES MARKET SIZE, BY PERIPHERAL ARTERIAL THROMBOSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL THROMBECTOMY DEVICES MARKET SIZE, BY CORONARY ARTERY THROMBOSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL THROMBECTOMY DEVICES MARKET SIZE, BY CORONARY ARTERY THROMBOSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL THROMBECTOMY DEVICES MARKET SIZE, BY CORONARY ARTERY THROMBOSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL THROMBECTOMY DEVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. AMERICAS THROMBECTOMY DEVICES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 80. AMERICAS THROMBECTOMY DEVICES MARKET SIZE, BY SYSTEM TYPE, 2018-2032 (USD MILLION)
  • TABLE 81. AMERICAS THROMBECTOMY DEVICES MARKET SIZE, BY DEVICE COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 82. AMERICAS THROMBECTOMY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 83. AMERICAS THROMBECTOMY DEVICES MARKET SIZE, BY CLINICAL APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 84. AMERICAS THROMBECTOMY DEVICES MARKET SIZE, BY PERIPHERAL / VENOUS, 2018-2032 (USD MILLION)
  • TABLE 85. AMERICAS THROMBECTOMY DEVICES MARKET SIZE, BY NEUROVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 86. AMERICAS THROMBECTOMY DEVICES MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA THROMBECTOMY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA THROMBECTOMY DEVICES MARKET SIZE, BY SYSTEM TYPE, 2018-2032 (USD MILLION)
  • TABLE 89. NORTH AMERICA THROMBECTOMY DEVICES MARKET SIZE, BY DEVICE COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 90. NORTH AMERICA THROMBECTOMY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA THROMBECTOMY DEVICES MARKET SIZE, BY CLINICAL APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 92. NORTH AMERICA THROMBECTOMY DEVICES MARKET SIZE, BY PERIPHERAL / VENOUS, 2018-2032 (USD MILLION)
  • TABLE 93. NORTH AMERICA THROMBECTOMY DEVICES MARKET SIZE, BY NEUROVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA THROMBECTOMY DEVICES MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 95. LATIN AMERICA THROMBECTOMY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. LATIN AMERICA THROMBECTOMY DEVICES MARKET SIZE, BY SYSTEM TYPE, 2018-2032 (USD MILLION)
  • TABLE 97. LATIN AMERICA THROMBECTOMY DEVICES MARKET SIZE, BY DEVICE COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 98. LATIN AMERICA THROMBECTOMY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 99. LATIN AMERICA THROMBECTOMY DEVICES MARKET SIZE, BY CLINICAL APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 100. LATIN AMERICA THROMBECTOMY DEVICES MARKET SIZE, BY PERIPHERAL / VENOUS, 2018-2032 (USD MILLION)
  • TABLE 101. LATIN AMERICA THROMBECTOMY DEVICES MARKET SIZE, BY NEUROVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 102. LATIN AMERICA THROMBECTOMY DEVICES MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA THROMBECTOMY DEVICES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA THROMBECTOMY DEVICES MARKET SIZE, BY SYSTEM TYPE, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA THROMBECTOMY DEVICES MARKET SIZE, BY DEVICE COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA THROMBECTOMY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA THROMBECTOMY DEVICES MARKET SIZE, BY CLINICAL APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA THROMBECTOMY DEVICES MARKET SIZE, BY PERIPHERAL / VENOUS, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA THROMBECTOMY DEVICES MARKET SIZE, BY NEUROVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE, MIDDLE EAST & AFRICA THROMBECTOMY DEVICES MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE THROMBECTOMY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE THROMBECTOMY DEVICES MARKET SIZE, BY SYSTEM TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE THROMBECTOMY DEVICES MARKET SIZE, BY DEVICE COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE THROMBECTOMY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE THROMBECTOMY DEVICES MARKET SIZE, BY CLINICAL APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE THROMBECTOMY DEVICES MARKET SIZE, BY PERIPHERAL / VENOUS, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE THROMBECTOMY DEVICES MARKET SIZE, BY NEUROVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE THROMBECTOMY DEVICES MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 119. MIDDLE EAST THROMBECTOMY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. MIDDLE EAST THROMBECTOMY DEVICES MARKET SIZE, BY SYSTEM TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. MIDDLE EAST THROMBECTOMY DEVICES MARKET SIZE, BY DEVICE COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 122. MIDDLE EAST THROMBECTOMY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 123. MIDDLE EAST THROMBECTOMY DEVICES MARKET SIZE, BY CLINICAL APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 124. MIDDLE EAST THROMBECTOMY DEVICES MARKET SIZE, BY PERIPHERAL / VENOUS, 2018-2032 (USD MILLION)
  • TABLE 125. MIDDLE EAST THROMBECTOMY DEVICES MARKET SIZE, BY NEUROVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 126. MIDDLE EAST THROMBECTOMY DEVICES MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 127. AFRICA THROMBECTOMY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 128. AFRICA THROMBECTOMY DEVICES MARKET SIZE, BY SYSTEM TYPE, 2018-2032 (USD MILLION)
  • TABLE 129. AFRICA THROMBECTOMY DEVICES MARKET SIZE, BY DEVICE COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 130. AFRICA THROMBECTOMY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 131. AFRICA THROMBECTOMY DEVICES MARKET SIZE, BY CLINICAL APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 132. AFRICA THROMBECTOMY DEVICES MARKET SIZE, BY PERIPHERAL / VENOUS, 2018-2032 (USD MILLION)
  • TABLE 133. AFRICA THROMBECTOMY DEVICES MARKET SIZE, BY NEUROVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 134. AFRICA THROMBECTOMY DEVICES MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC THROMBECTOMY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC THROMBECTOMY DEVICES MARKET SIZE, BY SYSTEM TYPE, 2018-2032 (USD MILLION)
  • TABLE 137. ASIA-PACIFIC THROMBECTOMY DEVICES MARKET SIZE, BY DEVICE COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC THROMBECTOMY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC THROMBECTOMY DEVICES MARKET SIZE, BY CLINICAL APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 140. ASIA-PACIFIC THROMBECTOMY DEVICES MARKET SIZE, BY PERIPHERAL / VENOUS, 2018-2032 (USD MILLION)
  • TABLE 141. ASIA-PACIFIC THROMBECTOMY DEVICES MARKET SIZE, BY NEUROVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 142. ASIA-PACIFIC THROMBECTOMY DEVICES MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL THROMBECTOMY DEVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 144. ASEAN THROMBECTOMY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. ASEAN THROMBECTOMY DEVICES MARKET SIZE, BY SYSTEM TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. ASEAN THROMBECTOMY DEVICES MARKET SIZE, BY DEVICE COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 147. ASEAN THROMBECTOMY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 148. ASEAN THROMBECTOMY DEVICES MARKET SIZE, BY CLINICAL APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 149. ASEAN THROMBECTOMY DEVICES MARKET SIZE, BY PERIPHERAL / VENOUS, 2018-2032 (USD MILLION)
  • TABLE 150. ASEAN THROMBECTOMY DEVICES MARKET SIZE, BY NEUROVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 151. ASEAN THROMBECTOMY DEVICES MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 152. GCC THROMBECTOMY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. GCC THROMBECTOMY DEVICES MARKET SIZE, BY SYSTEM TYPE, 2018-2032 (USD MILLION)
  • TABLE 154. GCC THROMBECTOMY DEVICES MARKET SIZE, BY DEVICE COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 155. GCC THROMBECTOMY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 156. GCC THROMBECTOMY DEVICES MARKET SIZE, BY CLINICAL APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 157. GCC THROMBECTOMY DEVICES MARKET SIZE, BY PERIPHERAL / VENOUS, 2018-2032 (USD MILLION)
  • TABLE 158. GCC THROMBECTOMY DEVICES MARKET SIZE, BY NEUROVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 159. GCC THROMBECTOMY DEVICES MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPEAN UNION THROMBECTOMY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPEAN UNION THROMBECTOMY DEVICES MARKET SIZE, BY SYSTEM TYPE, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPEAN UNION THROMBECTOMY DEVICES MARKET SIZE, BY DEVICE COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPEAN UNION THROMBECTOMY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPEAN UNION THROMBECTOMY DEVICES MARKET SIZE, BY CLINICAL APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPEAN UNION THROMBECTOMY DEVICES MARKET SIZE, BY PERIPHERAL / VENOUS, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPEAN UNION THROMBECTOMY DEVICES MARKET SIZE, BY NEUROVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPEAN UNION THROMBECTOMY DEVICES MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 168. BRICS THROMBECTOMY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 169. BRICS THROMBECTOMY DEVICES MARKET SIZE, BY SYSTEM TYPE, 2018-2032 (USD MILLION)
  • TABLE 170. BRICS THROMBECTOMY DEVICES MARKET SIZE, BY DEVICE COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 171. BRICS THROMBECTOMY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 172. BRICS THROMBECTOMY DEVICES MARKET SIZE, BY CLINICAL APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 173. BRICS THROMBECTOMY DEVICES MARKET SIZE, BY PERIPHERAL / VENOUS, 2018-2032 (USD MILLION)
  • TABLE 174. BRICS THROMBECTOMY DEVICES MARKET SIZE, BY NEUROVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 175. BRICS THROMBECTOMY DEVICES MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 176. G7 THROMBECTOMY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 177. G7 THROMBECTOMY DEVICES MARKET SIZE, BY SYSTEM TYPE, 2018-2032 (USD MILLION)
  • TABLE 178. G7 THROMBECTOMY DEVICES MARKET SIZE, BY DEVICE COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 179. G7 THROMBECTOMY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 180. G7 THROMBECTOMY DEVICES MARKET SIZE, BY CLINICAL APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 181. G7 THROMBECTOMY DEVICES MARKET SIZE, BY PERIPHERAL / VENOUS, 2018-2032 (USD MILLION)
  • TABLE 182. G7 THROMBECTOMY DEVICES MARKET SIZE, BY NEUROVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 183. G7 THROMBECTOMY DEVICES MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 184. NATO THROMBECTOMY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 185. NATO THROMBECTOMY DEVICES MARKET SIZE, BY SYSTEM TYPE, 2018-2032 (USD MILLION)
  • TABLE 186. NATO THROMBECTOMY DEVICES MARKET SIZE, BY DEVICE COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 187. NATO THROMBECTOMY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 188. NATO THROMBECTOMY DEVICES MARKET SIZE, BY CLINICAL APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 189. NATO THROMBECTOMY DEVICES MARKET SIZE, BY PERIPHERAL / VENOUS, 2018-2032 (USD MILLION)
  • TABLE 190. NATO THROMBECTOMY DEVICES MARKET SIZE, BY NEUROVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 191. NATO THROMBECTOMY DEVICES MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 192. GLOBAL THROMBECTOMY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 193. UNITED STATES THROMBECTOMY DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 194. UNITED STATES THROMBECTOMY DEVICES MARKET SIZE, BY SYSTEM TYPE, 2018-2032 (USD MILLION)
  • TABLE 195. UNITED STATES THROMBECTOMY DEVICES MARKET SIZE, BY DEVICE COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 196. UNITED STATES THROMBECTOMY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 197. UNITED STATES THROMBECTOMY DEVICES MARKET SIZE, BY CLINICAL APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 198. UNITED STATES THROMBECTOMY DEVICES MARKET SIZE, BY PERIPHERAL / VENOUS, 2018-2032 (USD MILLION)
  • TABLE 199. UNITED STATES THROMBECTOMY DEVICES MARKET SIZE, BY NEUROVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 200. UNITED STATES THROMBECTOMY DEVICES MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 201. CHINA THROMBECTOMY DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 202. CHINA THROMBECTOMY DEVICES MARKET SIZE, BY SYSTEM TYPE, 2018-2032 (USD MILLION)
  • TABLE 203. CHINA THROMBECTOMY DEVICES MARKET SIZE, BY DEVICE COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 204. CHINA THROMBECTOMY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 205. CHINA THROMBECTOMY DEVICES MARKET SIZE, BY CLINICAL APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 206. CHINA THROMBECTOMY DEVICES MARKET SIZE, BY PERIPHERAL / VENOUS, 2018-2032 (USD MILLION)
  • TABLE 207. CHINA THROMBECTOMY DEVICES MARKET SIZE, BY NEUROVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 208. CHINA THROMBECTOMY DEVICES MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)